UNSPSC 51182001: Finasteride

This classification denotes a 5 alpha-reductase inhibitor and anti-androgen with the molecular formula C23H36N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57GNO57U7G, chemically known as 4-azaandrost-1-ene-17-carboxamide, n-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- but generally known as finasteride, which bears US NIH Compound Identifier 57363. European Medicines Agency schedules Finasteride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07629MIG.

UNSPSC 51182001 Finasteride is a Commodity code capturing state and local procurement of the pharmaceutical finasteride, used primarily to treat benign prostatic hyperplasia and male pattern baldness. State and local governments purchase finasteride through their health departments, corrections systems, and public health agencies as part of formulary management and inmate or patient medication supply. The drug is typically sourced through state pharmaceutical contracts, cooperative purchasing agreements, and standing supply arrangements rather than individual project-based solicitations, meaning procurement volumes and pricing are often negotiated at the state or regional level with manufacturers or authorized distributors.

The source provides no recent state or local contract opportunities under this code. Finasteride procurement at the state and local level tends to operate through evergreen pharmaceutical supply agreements and formulary updates rather than time-bound RFPs or IFBs, limiting the visibility of individual solicitations in typical opportunity databases. Business development professionals should track state health department pharmaceutical bidding cycles, corrections department medication supply RFQs, and cooperative purchasing vehicle updates (such as state pharmaceutical alliances) to identify entry points under this code.